HomeCompareRTNXF vs EPRT

RTNXF vs EPRT: Dividend Comparison 2026

RTNXF yields 2500.00% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RTNXF wins by $80609755877.30M in total portfolio value
10 years
RTNXF
RTNXF
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full RTNXF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — RTNXF vs EPRT

📍 RTNXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRTNXFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RTNXF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RTNXF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RTNXF
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, RTNXF beats the other by $63,520,143,069,569,020.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RTNXF + EPRT for your $10,000?

RTNXF: 50%EPRT: 50%
100% EPRT50/50100% RTNXF
Portfolio after 10yr
$40304877938.72M
Annual income
$37,364,790,040,935,800.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

RTNXF
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
-22.6
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RTNXF buys
0
EPRT buys
0
No recent congressional trades found for RTNXF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRTNXFEPRT
Forward yield2500.00%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$80609755877.37M$63.4K
Annual income after 10y$74,729,580,081,858,750.00$12,840.73
Total dividends collected$80198875900.38M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: RTNXF vs EPRT ($10,000, DRIP)

YearRTNXF PortfolioRTNXF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$260,700$250,000.00$11,205$505.18+$249.5KRTNXF
2$6,370,070$6,091,121.50$12,672$682.46+$6.36MRTNXF
3$145,912,632$139,096,656.81$14,490$930.48+$145.90MRTNXF
4$3,133,830,814$2,977,704,297.75$16,786$1,282.69+$3133.81MRTNXF
5$63,122,812,060$59,769,613,088.96$19,753$1,791.56+$63122.79MRTNXF
6$1,192,683,724,131$1,125,142,315,226.76$23,677$2,541.64+$1192683.70MRTNXF
7$21,144,559,711,004$19,868,388,126,183.19$29,008$3,672.99+$21144559.68MRTNXF
8$351,818,906,448,043$329,194,227,557,269.44$36,463$5,425.08+$351818906.41MRTNXF
9$5,495,491,397,671,320$5,119,045,167,771,913.00$47,238$8,221.57+$5495491397.62MRTNXF
10$80,609,755,877,367,070$74,729,580,081,858,750.00$63,385$12,840.73+$80609755877.30MRTNXF

RTNXF vs EPRT: Complete Analysis 2026

RTNXFStock

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Full RTNXF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this RTNXF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RTNXF vs SCHDRTNXF vs JEPIRTNXF vs ORTNXF vs KORTNXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.